These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 32310169)
41. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Maher-Edwards G; Zvartau-Hind M; Hunter AJ; Gold M; Hopton G; Jacobs G; Davy M; Williams P Curr Alzheimer Res; 2010 Aug; 7(5):374-85. PubMed ID: 20043816 [TBL] [Abstract][Full Text] [Related]
43. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease. Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S; Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428 [TBL] [Abstract][Full Text] [Related]
44. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576 [TBL] [Abstract][Full Text] [Related]
49. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Mecocci P; Bladström A; Stender K Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640 [TBL] [Abstract][Full Text] [Related]
50. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E; Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468 [TBL] [Abstract][Full Text] [Related]
51. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716 [TBL] [Abstract][Full Text] [Related]
52. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Feldman HH; Lane R; J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1056-63. PubMed ID: 17353259 [TBL] [Abstract][Full Text] [Related]